Human Metabolome Technologies, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Human Metabolome Technologies, Inc.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 9% in 3 years, but profit fell: ¥70 less profit per ¥100 of extra sales. Lower than 95% of Healthcare companies in Japan.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 43% of its market value (net cash). Higher than 88% of Healthcare companies in Japan.
Where ¥100 of sales goes
Latest year (Jun 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥117Over the last 3 years, every ¥100 of reported profit came with ¥117 of operating cash.
Lower than 57% of Healthcare companies in Japan.
Self-Funding Ratio
3.1×Over the last 3 years its own operating cash covered its investment spending (capex) 3.1 times.
Higher than 76% of Healthcare companies in Japan.
Cash Locked Ratio
¥9For every ¥100 of sales, ¥9 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥5 tied up three years earlier.
Less money tied up than 62% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 76% of Healthcare companies in Japan.
Growth Efficiency Ratio
−¥70Sales grew 9% in 3 years, but profit fell: ¥70 less profit per ¥100 of extra sales.
Lower than 95% of Healthcare companies in Japan.
Asset Productivity Ratio
+9% / -0%In 3 years sales changed by +9% while total assets changed by -0%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
2.1×Debt due within a year is covered 2.1 times by its yearly operating cash.
Higher than 71% of Healthcare companies in Japan.
Cash Cushion Ratio
+43%Cash, after subtracting all debt, equals 43% of its market value (net cash).
Higher than 88% of Healthcare companies in Japan.
Tangible Assets Ratio
99%Of every ¥100 the company owns, ¥99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in Japan.
Tangible Net Worth Ratio
98%Of every ¥100 of net worth, ¥98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 71% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Human Metabolome Technologies, Inc. owes ¥0.20 for every ¥1 it owns. Net profit fell 22% in the year to Jun 2026, and shrank 11% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Jun 2026.
P/E ratio
16.8Investors pay ¥16.8 for every ¥1 of Human Metabolome Technologies, Inc.'s yearly profit, higher than 54% of Healthcare companies in Japan.
P/B ratio
1.73The share price is 1.73 times Human Metabolome Technologies, Inc.'s book value per share, higher than 57% of Healthcare companies in Japan.
Market cap
¥3.2 BThe total market value of all of Human Metabolome Technologies, Inc.'s shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥1.8 BWhat Human Metabolome Technologies, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥340.10Net worth divided by the number of shares. The share price of ¥588.00 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
10.7%Human Metabolome Technologies, Inc. earned 10.7% on its shareholders' money over the last year, higher than 68% of Healthcare companies in Japan.
Owes vs Owns
0.20×Human Metabolome Technologies, Inc. owes ¥0.20 for every ¥1 it owns (low), lower than 77% of Healthcare companies in Japan.
Dividend yield
3.05%Human Metabolome Technologies, Inc. pays 3.05% of its share price as dividends a year, higher than 57% of dividend-paying Healthcare companies in Japan.
Revenue growth
-2%Revenue fell 2% in the year to Jun 2026, and grew 3% a year on average over 3 years.
Profit growth
-22%Net profit fell 22% in the year to Jun 2026, and shrank 11% a year on average over 3 years.
Profit margin
14.1%Human Metabolome Technologies, Inc. keeps ¥14 of every ¥100 of revenue as net profit.
Cash quality
1.04×Cash from Human Metabolome Technologies, Inc.'s business was 1.04× its reported profit in the year to Jun 2026 — its profit turned into cash.
Interest cover
105.9×Human Metabolome Technologies, Inc.'s operating profit covered its interest costs 105.9 times in the year to Jun 2026.
Cash vs debt
Net cashHuman Metabolome Technologies, Inc. held ¥1.3 B more cash than debt (net cash) at Jun 2026.
Questions
What is Human Metabolome Technologies, Inc.'s P/E ratio?
Investors pay ¥16.8 for every ¥1 of Human Metabolome Technologies, Inc.'s yearly profit, higher than 54% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Human Metabolome Technologies, Inc.: ¥3.2 B ÷ ¥1.8 B (30 Jun 2026) = 1.7.
What is Human Metabolome Technologies, Inc.'s return on equity?
Human Metabolome Technologies, Inc. earned 10.7% on its shareholders' money over the last year, higher than 68% of Healthcare companies in Japan.
How much does Human Metabolome Technologies, Inc. owe compared with what it owns?
Human Metabolome Technologies, Inc. owes ¥0.20 for every ¥1 it owns (low), lower than 77% of Healthcare companies in Japan.
Does Human Metabolome Technologies, Inc. pay a dividend?
Yes. Human Metabolome Technologies, Inc. pays 3.05% of its share price as dividends a year, higher than 57% of dividend-paying Healthcare companies in Japan.
Is Human Metabolome Technologies, Inc.'s revenue growing?
Revenue fell 2% in the year to Jun 2026, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.